Illumina Reports Drop in Preliminary Q3 Revenues | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market on Thursday a drop in preliminary revenues of almost 1 percent year over year for the third quarter.

The San Diego-based firm said that it estimates revenues for the third quarter to come in at around $235 million, compared to $237.3 million from a year ago. That figure also is well below the Wall Street consensus estimate of $277.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.